Akela Pharma to repeat Fentanyl TAIDUN tests at request of FDA « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

Akela Pharma to repeat Fentanyl TAIDUN tests at request of FDA

Posted on July 15, 2008 by crimsoncanary

Akela Pharma have announced that it will repeat required inhalation toxicology studies at the request of the FDA before commencing long term safety Phase III trials

Filed under: gpcr | Tagged: Akela Pharma, Fentanyl, kappa opioid, Opioid, TAIDUN

« Univ Maryland publish series of Nociceptin/Orphanin FQ(1−13) Amide Analogues Phase II data show 5HT1D agonist MAP0004 is effective in Migraine »

Leave a Reply